Artios Pharma Raises $115 Million Series D to Advance DNA Damage Response Cancer Therapies
Artios Pharma; Series D financing; DNA Damage Response (DDR); cancer therapies; alnodesertib; ART6043; oncology pipeline; pancreatic cancer; colorectal cancer; breast cancer; investors; clinical trials
Solve Therapeutics Raises $120M to Advance Next-Generation ADCs for Solid Tumors
Solve Therapeutics; antibody-drug conjugates; ADC; CloakLink linker technology; solid tumors; oncology; SLV-154; SLV-324; clinical trials; venture capital; Yosemite; Merck
Eli Lilly to Acquire Adverum Biotechnologies in Gene Therapy Deal; Captain T Cell Secures €20M Funding
Eli Lilly; Adverum Biotechnologies; Acquisition; Gene therapy; Ixo-vec; Contingent Value Rights (CVR); Ophthalmology; Captain T Cell; Financing; Biotech investment
Terray Therapeutics Unveils EMMI: AI-Driven Platform Revolutionizes Small Molecule Drug Discovery
Terray Therapeutics; EMMI; generative AI; small molecule drug discovery; AI-native platform; chemical space; drug optimization; biotech; machine learning; COATI model
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)
Bright Minds Biosciences; Scientific Advisory Board; Prader-Willi Syndrome; PWS; BMB-101; BMB-105; clinical trials; neurodevelopmental disorders
NewcelX Appoints Jeremy Shefner to Scientific Advisory Board
NewcelX; Jeremy Shefner; Scientific Advisory Board; ALS; AstroRx; neurodegenerative disease; Barrow Neurological Institute; cell therapy; clinical trials
Sandoz Launches Tyruko (Natalizumab-Sztn), First Tysabri Biosimilar, in US After JCV Assay Delays
Sandoz; Tyruko; Tysabri biosimilar; natalizumab-sztn; multiple sclerosis (MS); biosimilar launch; JCV assay; progressive multifocal leukoencephalopathy (PML); FDA approval; Polpharma Biologics
Lunit and Labcorp Partner to Transform Tumor Microenvironment Analysis with AI-Powered Digital Pathology
Lunit; Labcorp; artificial intelligence; digital pathology; tumor microenvironment; spatial profiling; biomarker discovery; precision oncology; non-small cell lung cancer (NSCLC); MET exon 14 skipping mutation
Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion to Add RIPTAC Cancer Drug Platform
Johnson & Johnson; Halda Therapeutics; acquisition; RIPTAC; HLD-0915; prostate cancer; targeted protein degradation; oncology; clinical pipeline
Eli Lilly Signs Up to $2.6 Billion Deal with South Korean Biotech for RNA Medicine Delivery
Eli Lilly; SanegeneBio; South Korean biotech; RNAi medicines; metabolic diseases; LEAD platform; strategic partnership; cardiometabolic; deal value; pharma news